<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642980</url>
  </required_header>
  <id_info>
    <org_study_id>060216</org_study_id>
    <secondary_id>PHRC 2004/1918</secondary_id>
    <secondary_id>PHRC 2008/1929</secondary_id>
    <secondary_id>2004/0428</secondary_id>
    <nct_id>NCT00642980</nct_id>
  </id_info>
  <brief_title>Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis</brief_title>
  <acronym>PREMEVA</acronym>
  <official_title>Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background. Anomalies of the vaginal flora (bacterial vaginosis, BV) are associated with an
      increased risk of late abortions and preterm birth. Studies of antibiotic treatment of BV to
      reduce the risk of prematurity have not found a statistically significant diminution of risk
      (&lt;= 32 wks: OR=0.49 [0.05-5.1], &lt; 37 wks: OR=0.83 [0.59-1.17]).A partial explanation of these
      findings is that some of these treatment were administered vaginally, most often during the
      second or third trimester

      Aim: To reduce the frequency of late abortions and very preterm birth by prescribing
      clindamycin vs placebo to patients diagnosed with BV before 13 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients diagnosed with BV before 13 weeks will be divided into two groups. They will be
      defined as at low risk when they have no history of spontaneous preterm delivery or late
      abortion. Women with such histories will be defined as at high risk.

      Low risk patients will be asked to participate in a trial with 3 equal parallel groups,
      comparing two regimes of clindamycin (one or three 4-day treatments of clindamycin 300
      mgx2/d) and placebo.

      High-risk patients will be asked to participate in a trial with 2 parallel groups to assess
      the usefulness of repeating antibiotic treatment monthly by comparing the administration of
      one 4-day treatment of clindamycin (300 mgx2/d) to three 4-day treatments, one month apart.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Premature delivery (16 to 32 weeks of gestation)</measure>
    <time_frame>At delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm labor, PPROM, Spontaneous preterm labor, PROM, Abruptio placentae, Chorioamnionitis, Fever &gt; 38°C during labor, Post partum fever (&gt; 38°), Post-partum wound infections, Perinatal death, NICU transfer, Bacterial neonatal colonisation.</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3105</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Clindamycin Cure 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clindamycin Cure 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart</description>
    <arm_group_label>Clindamycin Cure 1</arm_group_label>
    <other_name>non applicable</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>non applicable</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart</description>
    <arm_group_label>Clindamycin Cure 2</arm_group_label>
    <other_name>non applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nugent score &gt;= 7

          -  pregnant women &lt; 15 weeks (strictly)

          -  signed informed consent

          -  &gt;=18 old

          -  speaking and understanding French language

        Exclusion Criteria:

          -  metrorrhagias during 7 days before

          -  birth anticipated in an other area

          -  clindamycin allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damien SUBTIL, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille (France)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles Brabant, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Groupe Hospitalier de l' Institut Catholique, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Preterm delivery</keyword>
  <keyword>Bacterial vaginosis</keyword>
  <keyword>Randomized Clinical Trial</keyword>
  <keyword>Clindamycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

